JP2015533374A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533374A5
JP2015533374A5 JP2015537841A JP2015537841A JP2015533374A5 JP 2015533374 A5 JP2015533374 A5 JP 2015533374A5 JP 2015537841 A JP2015537841 A JP 2015537841A JP 2015537841 A JP2015537841 A JP 2015537841A JP 2015533374 A5 JP2015533374 A5 JP 2015533374A5
Authority
JP
Japan
Prior art keywords
chain variable
variable domain
light chain
sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015537841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533374A (ja
Filing date
Publication date
Priority claimed from US13/830,844 external-priority patent/US9309318B2/en
Application filed filed Critical
Publication of JP2015533374A publication Critical patent/JP2015533374A/ja
Publication of JP2015533374A5 publication Critical patent/JP2015533374A5/ja
Pending legal-status Critical Current

Links

JP2015537841A 2012-10-17 2013-10-17 抗ｉｌ−２１受容体抗体に関連する方法および組成物 Pending JP2015533374A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261715156P 2012-10-17 2012-10-17
US61/715,156 2012-10-17
US13/830,844 2013-03-14
US13/830,844 US9309318B2 (en) 2012-10-17 2013-03-14 Compositions relating to anti-IL-21 receptor antibodies
PCT/US2013/065514 WO2014062963A1 (en) 2012-10-17 2013-10-17 Methods and compositions relating to anti-il-21 receptor antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018014989A Division JP2018102302A (ja) 2012-10-17 2018-01-31 抗ｉｌ−２１受容体抗体に関連する方法および組成物

Publications (2)

Publication Number Publication Date
JP2015533374A JP2015533374A (ja) 2015-11-24
JP2015533374A5 true JP2015533374A5 (enExample) 2016-11-17

Family

ID=50475498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015537841A Pending JP2015533374A (ja) 2012-10-17 2013-10-17 抗ｉｌ−２１受容体抗体に関連する方法および組成物
JP2018014989A Pending JP2018102302A (ja) 2012-10-17 2018-01-31 抗ｉｌ−２１受容体抗体に関連する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018014989A Pending JP2018102302A (ja) 2012-10-17 2018-01-31 抗ｉｌ−２１受容体抗体に関連する方法および組成物

Country Status (8)

Country Link
US (2) US9309318B2 (enExample)
EP (2) EP3424954A1 (enExample)
JP (2) JP2015533374A (enExample)
AU (1) AU2013331139B2 (enExample)
CA (1) CA2888617A1 (enExample)
HK (1) HK1214279A1 (enExample)
MX (1) MX2015004892A (enExample)
WO (1) WO2014062963A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
CA2148907C (en) 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6828422B1 (en) * 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
CN102149403A (zh) 2008-05-23 2011-08-10 惠氏有限责任公司 利用白介素-21受体结合蛋白的治疗方法
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CN102532320A (zh) 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Similar Documents

Publication Publication Date Title
JP7254699B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP6893970B2 (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
US11365260B2 (en) Agonistic 4-1BB monoclonal antibody
JP6604204B2 (ja) 新規抗ヒトｂｄｃａ−２抗体
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
RU2011145428A (ru) АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
KR20160044063A (ko) 항-pd1 항체 및 이의 치료 및 진단 용도
JP2012526558A5 (enExample)
US20210188989A1 (en) Anti-4-1bb antibodies and methods of making and using thereof
JP2018519364A5 (enExample)
CN107921128B (zh) 抗cd154抗体及其使用方法
RU2017102514A (ru) Гуманизированные анти-тау-антитела
CN108367075A (zh) 4-1bb结合蛋白及其用途
JP2016513467A5 (enExample)
JP2012524071A5 (enExample)
JP2007054079A (ja) ヒトｍｃｐ−１に対する抗体
DK2643352T3 (en) Antigen Binding Proteins for Oncostatin M (OSM)
Sadeghalvad et al. Introduction on monoclonal antibodies
RU2007143996A (ru) Антитела против il2
CN111886023A (zh) 针对tim-3的抗体及其用途
CN109641966A (zh) 抗il-22r抗体
WO2016021621A1 (ja) 新規抗ヒトＩｇβ抗体
Sandeep et al. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
JP2024533234A5 (enExample)
TW201904999A (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途